By crossing the sequencing data obtained from EGFR‐inhibitor‐resistant cell lines with those deriving from patients, we were able to establish that the activation of the EGFR downstream signaling pathway by RAS or BRAF mutations also constituted the main mechanism of acquired resistance to EGFR inhibitors in CRC [9, 10]. The gene discussed is BRAF; the disease is colorectal carcinoma.